Article
Medicine, General & Internal
Renaud Sabatier, Johan Martin, Cecile Vicier, Mathilde Guerin, Audrey Monneur, Magali Provansal, Louis Tassy, Carole Tarpin, Jean-Marc Extra, Frederic Viret, Anthony Goncalves
Summary: In advanced breast cancer patients, the efficacy of eribulin on brain metastases is limited, with only some patients experiencing disease stabilization or partial response. Hormone receptor expression can identify a subset of patients with better control of brain metastases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Audrey Perret, Julien Domont, Ali N. Chamseddine, Sarah N. Dumont, Benjamin Verret, Sylvain Briand, Charles Court, Thierry Lazure, Julien Adam, Carine Ngo, Caroline Even, Antonin Levy, Arnaud Bayle, Francesca Lucibello, Leila Haddag-Miliani, Matthieu Faron, Charles Honore, Axel Le Cesne, Olivier Mir
Summary: Oral metronomic etoposide has shown effective palliation with acceptable toxicity in patients with progressive metastatic osteosarcoma, improving survival rates and disease control rates.
Article
Oncology
Nanlin Hu, Anjie Zhu, Yiran Si, Jian Yue, Xue Wang, Jiayu Wang, Fei Ma, Binghe Xu, Peng Yuan
Summary: The combination of apatinib and etoposide capsules is effective and tolerable in treating heavily pretreated, metastatic HER2-negative breast cancer patients. A lower dose of apatinib provides equivalent efficacy and reduced toxicity.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Clelia Chalumeau, Matthieu Carton, Alexandre Eeckhoutte, Stelly Ballet, Anne Vincent-Salomon, Perrine Vuagnat, Audrey Bellesoeur, Jean-Yves Pierga, Marc-Henri Stern, Francois-Clement Bidard, Florence Lerebours
Summary: This retrospective analysis evaluated the impact of oral VP16-trastuzumab on HER2+ MBC patients and assessed the co-amplification status of TOP2A/ERBB2. The results showed that the oral VP16-trastuzumab regimen has favorable efficacy and tolerability in heavily pretreated HER2+ MBC patients.
Article
Oncology
V Boni, B. Pistilli, I Brana, G. Shapiro, J. Trigo, V Moreno, D. Castellano, C. Fernandez, C. Kahatt, V Alfaro, M. Siguero, A. Zeaiter, F. Longo, K. Zaman, A. Anton, A. Paredes, G. Huidobro, V Subbiah
Summary: This study demonstrates the activity of Lurbinectedin in pretreated germline BRCA1/2 breast cancer patients and its predictable and manageable safety profile. BRCA2 mutations showed a higher partial response rate compared to BRCA1. Further development of Lurbinectedin in this indication is warranted considering the exploratory aim of this trial and previous results from other phase II studies.
Article
Oncology
Mengru Cao, Hailing Lu, Shi Yan, Hui Pang, Lichun Sun, Chunhong Li, Xuesong Chen, Wei Liu, Jing Hu, Jian Huang, Ying Xing, Ningzhi Zhang, Yingqi Chen, Ting He, Danni Zhao, Yuanyuan Sun, Lin Zhao, Xiaomeng Liu, Li Cai
Summary: This study evaluated the efficacy and safety of the combination of apatinib, an antiangiogenic agent, and etoposide in treating advanced triple-negative breast cancer. The results showed that the combination therapy prolonged progression-free survival and had acceptable adverse events.
Article
Oncology
Zhaoyun Liu, Jing Shan, Qian Yu, Xinzhao Wang, Xiang Song, Fukai Wang, Chao Li, Zhiyong Yu, Jinming Yu
Summary: This study evaluated the safety and efficacy of apatinib in metastatic breast cancer patients pretreated with multiline treatment, showing moderate efficacy with no significant treatment-related adverse events. Apatinib may be considered as a maintenance salvage therapy for women following multiline chemotherapy failure.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yannan Zhao, Ning Xie, Wei Li, Wenyan Chen, Zheng Lv, Yabing Zheng, Tao Sun, Jieqiong Liu, Jian Zhang, Shihui Hu, Yajun Wang, Chengcheng Gong, Yi Li, Yizhao Xie, Rui Ge, Fei Xu, Biyun Wang
Summary: Eribulin demonstrated effective outcomes with manageable toxicity profile in Chinese women with metastatic breast cancer, and did not increase toxic effects when used in combination with other agents.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
A. H. Awada, V Boni, V Moreno, P. Aftimos, C. Kahatt, X. E. Luepke-Estefan, M. Siguero, C. Fernandez-Teruel, M. Cullell-Young, J. Tabernero
Summary: This study evaluated the efficacy of the combination of capecitabine and lurbinectedin in patients with relapsed metastatic breast cancer. The results showed encouraging clinical activity, particularly in patients with hormone receptor-positive tumors. Toxicity was manageable at the recommended dose. Further research is needed.
Article
Oncology
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Summary: The combination of orally administered metronomic capecitabine and pyrotinib in HER2 positive metastatic breast cancer patients shows promising efficacy and improved tolerability.
Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo, Julie R. Gralow, Gabriel N. Hortobagyi, Douglas Yee, Ian E. Smith, Mariana Chavez-MacGregor, Rita Nanda, Heather L. McArthur, Laura Spring, Katherine E. Reeder-Hayes, Kathryn J. Ruddy, Paul S. Unger, Shaveta Vinayak, William J. Irvin, Avan Armaghani, Michael A. Danso, Natalie Dickson, Sophie S. Turner, Cheryl L. Perkins, Lisa A. Carey
Summary: This guideline provides recommendations on chemotherapy and targeted therapy for patients with HR-negative metastatic breast cancer, offering different treatment options based on patient's condition, such as combination chemotherapy, single-agent chemotherapy, or targeted therapy. Specific treatment options are also suggested for patients with different genetic mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Tie Zhou, Shengfei Qin, Weidong Xu, Shouyan Tang, Guanghua Chen, Song Li, Jianguo Hou, Xu Gao, Guowei Shi, Zhongquan Sun, Jie Jin, Lijun Chen, Weibing Sun, Ben Liu, Jingen Wang, Qinggui Meng, Dongwen Wang, Zhiquan Hu, Dalin He, Yong Yang, Xishuang Song, Cheng Fu, Yinhuai Wang, Dingwei Ye, Wei Zhang
Summary: This study assessed the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, in men with metastatic castration-resistant prostate cancer (mCRPC). By evaluating various endpoints, it was found that the 200 mg dose group showed the best antitumor activity with manageable safety. Therefore, a daily dose of 200 mg proxalutamide is recommended for future phase 3 trials.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Hope S. Rugo, Aditya Bardia, Frederik Marme, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gomez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Audrey Mailliez, Veronique D'Hondt, Amelie Lusque, Olivier Caron, Luc Cabel, Anthony Goncalves, Marc Debled, Laurence Gladieff, Jean-Marc Ferrero, Thierry Petit, Marie Ange Mouret-Reynier, Jean-Christophe Eymard, Christelle Levy, Lionel Uwer, Marianne Leheurteur, Isabelle Desmoulins, Thomas Bachelot, Jean-Sebastien Frenel, Thibault de la Motte Rouge, Gaetane Simon, William Jacot, Suzette Delaloge
Summary: The outcomes and treatment strategies for germline BRCA1/2 mutation carriers with metastatic breast cancer are uncertain. This study found that in the triple-negative subtype, these patients had better overall survival and progression-free survival, while in HR+/HER2 negative cancers, their progression-free survival was significantly lower.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Engineering, Electrical & Electronic
Yongqiang Zhang, Jianbo He, Songtao Guo, Fei Wang
IET COMMUNICATIONS
(2018)
Article
Pharmacology & Pharmacy
Zhao Ming, Zhang Yongqiang, Zhang Zijin, Xu Yan, Chen Di, Tian Xiaoxin
Review
Medicine, General & Internal
Shao-lei Wang, Yuan-bin Hu, Hao Chen, Bo Tao, Guo-yun Bu, Yong-qiang Zhang, Jin-song Zhang
Article
Medicine, General & Internal
Zhigang Song, Chunkai Yu, Shuangmei Zou, Wenmiao Wang, Yong Huang, Xiaohui Ding, Jinhong Liu, Liwei Shao, Jing Yuan, Xiangnan Gou, Wei Jin, Zhanbo Wang, Xin Chen, Huang Chen, Cancheng Liu, Gang Xu, Zhuo Sun, Calvin Ku, Yongqiang Zhang, Xianghui Dong, Shuhao Wang, Wei Xu, Ning Lv, Huaiyin Shi
Article
Computer Science, Information Systems
Yongqiang Zhang, Jia Ye, Gaofeng Pan, Mohamed-Slim Alouini
IEEE WIRELESS COMMUNICATIONS LETTERS
(2020)
Review
Medicine, General & Internal
Yong-qiang Zhang, Zhao Zhang, Meng Wu, Ya-dong Zhou, Sheng-lin Tao, Ya-long Yang, Yang Li, Jun-liang Liu, Peng Li, Yun-sheng Teng, Yong-ming Guo
Summary: MPFL reconstruction is a reliable technique for the treatment of patellofemoral instability. The SchOttle point remains the mainstream method for determining the femoral attachment, with the patellar attachment for single-bundle located at the junction of the proximal one third and the distal two third of the longitudinal axis of the patella. For double-bundles, one is located at the proximal one third of the medial patellar edge and another is at the center of the patellar edge. Adjusting the graft tension during surgery is crucial.
Article
Environmental Sciences
Yongqiang Zhang, Lingli Qi, Xinyue Lin, Haoran Pan, Basil Sharp
Summary: This study examines the impact of different carbon emission reduction policies on achieving carbon emissions peak by using a dynamic computable general equilibrium model. The results show that a hybrid system of carbon tax and carbon ETS can help achieve the peak at a lower economic cost and promote optimization of energy consumption structures.
SCIENCE OF THE TOTAL ENVIRONMENT
(2022)
Article
Economics
Shiqi Jiang, Xinyue Lin, Lingli Qi, Yongqiang Zhang, Basil Sharp
Summary: The COVID-19 pandemic has had a significant impact on China's economy and carbon emissions. This study shows that a combination of loan prime rate reduction and value-added tax reduction is more effective in stimulating economic recovery than single policies. The VAT cut expands production, while lowering the loan prime rate mitigates the damage of demand-side shocks.
ECONOMIC ANALYSIS AND POLICY
(2022)
Article
Computer Science, Information Systems
Yongqiang Zhang, Mustafa A. Kishk, Mohamed-Slim Alouini
Summary: This paper investigates the impact of integrated access and backhaul (IAB) on mobile edge computing (MEC) networks by modeling a spatial-random two-tier heterogeneous network. Using stochastic geometry and queuing theory, the average delay for two different offloading strategies is derived and simulation results are provided to validate the derived expressions and gain system-level insights.
IEEE TRANSACTIONS ON MOBILE COMPUTING
(2023)
Article
Environmental Sciences
Lingli Qi, Xinyue Lin, Xile Shi, Yongqiang Zhang, Haoran Pan, Basil Sharp
Summary: The thermal power industry in China is a major source of carbon emissions. To achieve its peak emission target by 2030, China has implemented a national carbon emissions trading scheme (ETS) and renewable energy incentive programs. However, the removal of central feed-in tariffs (FIT) for certain renewable energy projects since 2021 may jeopardize China's carbon reduction targets and economic development. Using a dynamic computable general equilibrium (CGE) model, this study explores the combined effects of the carbon ETS and FIT on China's electricity sector, carbon emission peak target, renewable energy, and economic development. The results suggest that FIT subsidies have a more positive overall impact compared to phasing-out FIT scenarios.
JOURNAL OF ENVIRONMENTAL MANAGEMENT
(2023)
Article
Environmental Studies
Yongqiang Zhang, Shiqi Jiang, Xinyue Lin, Lingli Qi, Basil Sharp
Summary: China has implemented a national carbon emission trading scheme and aims to reach the peak of carbon emissions by 2030. Adding a carbon tax as a supplement to the carbon trading scheme may help achieve this goal by reducing income inequality among different labor forces. However, the burden of carbon pricing is greater on lower-income households compared to wealthier households.
ENVIRONMENTAL IMPACT ASSESSMENT REVIEW
(2023)
Article
Medicine, General & Internal
Chao Li, Shaoyuan Lei, Li Ding, Yan Xu, Xiaonan Wu, Hui Wang, Zijin Zhang, Ting Gao, Yongqiang Zhang, Lin Li
Summary: This study aimed to investigate the global patterns and trends of lung cancer. The burden of lung cancer is still unsatisfactory, especially in developing countries like China. The incidence and mortality rates of lung cancer vary among different countries and regions, with higher rates in men than in women. In developed countries such as the USA, the incidence of lung cancer has been decreasing, while in China, it has been increasing, particularly among individuals aged 50 to 59 years. Therefore, there is a need to strengthen health education, accelerate the establishment of tobacco control policies and regulations, and improve early cancer screening awareness to reduce the future burden of lung cancer.
CHINESE MEDICAL JOURNAL
(2023)
Article
Oncology
Yan Xu, Li Ding, Yong-Qiang Zhang
Summary: Certain clinical characteristics are associated with chemotherapy tolerance among elderly patients with advanced solid tumors, including minimal comorbidities, medications, high ADL score, and low PS score. Normal D-Dimer levels and serum albumin concentrations are also related to chemotherapy tolerance. Patients with good chemotherapy tolerance demonstrated significantly longer overall survival.
INDIAN JOURNAL OF CANCER
(2021)
Review
Telecommunications
Yongqiang Zhang, Mustafa A. Kishk, Mohamed-Slim Alouini
Summary: This paper discusses the research on IAB networks based on 3GPP specifications and possible non-3GPP research extensions, including integrating IAB networks with other advanced technologies and addressing the challenges and opportunities related to the development and commercialization of IAB networks.
FRONTIERS IN COMMUNICATIONS AND NETWORKS
(2021)
Article
Engineering, Electrical & Electronic
Gaofeng Pan, Jia Ye, Yongqiang Zhang, Mohamed-Slim Alouini
IEEE TRANSACTIONS ON WIRELESS COMMUNICATIONS
(2020)